MX2019000353A - Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer. - Google Patents

Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer.

Info

Publication number
MX2019000353A
MX2019000353A MX2019000353A MX2019000353A MX2019000353A MX 2019000353 A MX2019000353 A MX 2019000353A MX 2019000353 A MX2019000353 A MX 2019000353A MX 2019000353 A MX2019000353 A MX 2019000353A MX 2019000353 A MX2019000353 A MX 2019000353A
Authority
MX
Mexico
Prior art keywords
scaffolds
organ
cancer
biomatrix scaffolds
diagnosing
Prior art date
Application number
MX2019000353A
Other languages
English (en)
Inventor
M Reid Lola
Zhuang Wang Andrew
Tian Xi
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2019000353A publication Critical patent/MX2019000353A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

En este documento se describen modelos de metastasis de cancer in vitro que recapitulan facetas biologicas de especificidad de organos como lo indica el comportamiento de las celulas cancerosas colorrectales humanas cuando se encuentran en sustratos de andamiajes de biomatriz de higado y pulmon, extractos de matriz especificos de organos generados por nuevas estrategias de descelularizacion; las celulas tumorales formaron de manera espontanea colonias que imitaban las lesiones metastasicas in vivo en terminos de histologia, biologia y rasgos geneticos y otros fenotipicos; para no limitarse a la teoria, se postula que las respuestas de los tumores a la radiacion o los agentes quimioterapeuticos demostraron ser dependientes del sustrato de matriz utilizado; por lo tanto, se cree que los andamios proporcionan una herramienta poderosa para la investigacion y el diagnostico del cancer.
MX2019000353A 2016-07-12 2017-07-11 Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer. MX2019000353A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361306P 2016-07-12 2016-07-12
US201762460056P 2017-02-16 2017-02-16
PCT/US2017/041500 WO2018013542A1 (en) 2016-07-12 2017-07-11 Biomatrix scaffolds for use in diagnosing and modeling cancer

Publications (1)

Publication Number Publication Date
MX2019000353A true MX2019000353A (es) 2019-06-13

Family

ID=60953359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000353A MX2019000353A (es) 2016-07-12 2017-07-11 Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer.

Country Status (13)

Country Link
US (1) US20190234937A1 (es)
EP (1) EP3484487A4 (es)
JP (1) JP2019528682A (es)
KR (1) KR20190028726A (es)
CN (1) CN109843328A (es)
AU (1) AU2017296208A1 (es)
BR (1) BR112019000323A2 (es)
CA (1) CA3030166A1 (es)
IL (1) IL264117A (es)
MX (1) MX2019000353A (es)
RU (1) RU2019103382A (es)
SG (1) SG11201900057WA (es)
WO (1) WO2018013542A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092220A1 (en) * 2018-10-29 2020-05-07 The Jackson Laboratory Three dimensional human brain tumor models
WO2020237218A1 (en) * 2019-05-23 2020-11-26 Micro Vention, Inc. Particles
EP4146789A2 (en) * 2020-05-05 2023-03-15 Xylyx Bio, Inc. Devices and methods for in vitro modeling of metastatic cancer
EP4103697A4 (en) * 2020-11-03 2023-08-09 Iscaff Pharma AB USES OF PATIENT DERIVED SCAFFOLDS
CN113029728B (zh) * 2021-05-24 2021-09-10 北京恩泽康泰生物科技有限公司 一种使用冰冻切片机提高组织外泌体产量的方法
WO2023288102A1 (en) * 2021-07-15 2023-01-19 Cypre, Inc. Compositions and methods for improving treatment of cancer
WO2023151683A1 (en) * 2022-02-11 2023-08-17 Shanghaitech University Individualized patient-derived tumor organoids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255066A1 (en) * 1997-09-23 2008-10-16 Sarissa Inc. Antisense oligonucleotide strategies for the enhancement of cancer therapies
WO2007138098A2 (en) * 2006-05-31 2007-12-06 Projech Science To Technology, S.L. Animal models of tumour metastasis and toxicity
EP2588083B1 (en) * 2010-07-02 2017-03-08 The University of North Carolina at Chapel Hill Biomatrix scaffolds
EP2739971A1 (en) * 2011-08-02 2014-06-11 Roche Diagnostics GmbH In vitro tumor metastasis model
US20130344490A1 (en) * 2012-04-27 2013-12-26 Min Peter Kim Neoplastic cells grown on decellularized biomatrix
US20160032400A1 (en) * 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis

Also Published As

Publication number Publication date
IL264117A (en) 2019-02-28
RU2019103382A (ru) 2020-08-11
BR112019000323A2 (pt) 2019-04-16
CA3030166A1 (en) 2018-01-18
US20190234937A1 (en) 2019-08-01
JP2019528682A (ja) 2019-10-17
SG11201900057WA (en) 2019-02-27
AU2017296208A1 (en) 2019-02-21
WO2018013542A1 (en) 2018-01-18
KR20190028726A (ko) 2019-03-19
EP3484487A1 (en) 2019-05-22
EP3484487A4 (en) 2020-06-17
CN109843328A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
MX2019000353A (es) Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer.
ES2634546T3 (es) Uso de células madre mesenquimales modificadas genéticamente para expresar un gen suicida para tratar un cáncer
WO2018160768A8 (en) COMPOSITIONS AND METHODS FOR INHIBITING PROTEINS SPECIFIC TO A LINE
SA517380984B1 (ar) طريقة لإنتاج خلايا سليفة في كبد بالغ
NZ738689A (en) Engineered crispr-cas9 compositions and methods of use
BR112019014615A2 (pt) Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
WO2014172046A3 (en) Gene fusions and gene variants associated with cancer
MY180473A (en) Imaging and evaluating embryos, oocytes, and stem cells
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
MX2017006624A (es) Anticuerpos contra cd73 y sus usos.
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
GB2449772A (en) Large scale production of stem cells
MX2016002582A (es) Metodo para producir celulas progenitoras hepaticas adultas.
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
WO2020120442A3 (en) Direct oligonucleotide synthesis on cells and biomolecules
MX2018016051A (es) Composiciones y métodos para diagnosticar tipos de cáncer de pulmón usando perfiles de expresión génica.
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
MX2020006131A (es) Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos.
Hultman et al. Experimental teratoma: at the crossroad of fetal-and onco-development
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
Alladin et al. Towards a holistic and mechanistic understanding of tumourigenesis via genetically engineered mouse models